Stay updated on Nivolumab and Relatlimab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and Relatlimab in Melanoma Clinical Trial page.

Latest updates to the Nivolumab and Relatlimab in Melanoma Clinical Trial page
- Check4 days agoChange DetectedThe footer’s ClinicalTrials.gov revision identifier changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check11 days agoNo Change Detected
- Check17 days agoChange DetectedAccess to the study page now returns a 403 Forbidden error, displaying a 403 header and a Home link instead of the study details. The previous study content appears to be inaccessible on this page.SummaryDifference22%

- Check24 days agoChange DetectedA new page revision label 'Revision: v3.7.0' is now displayed, indicating an update to the page version. The old revision label 'Revision: v3.6.6' and related topics such as 'Melanoma' and 'MedlinePlus Genetics' were removed.SummaryDifference0.2%

- Check39 days agoChange DetectedThe study record adds posted results and a new Phase II description with expanded endpoints and timing for efficacy measurements (e.g., ORR, PFS, PD-1/LAG-3 expression, and tumor assessments).SummaryDifference9%

- Check46 days agoChange DetectedThe related topics section now lists Melanoma and MedlinePlus Genetics. This is a navigational/content enhancement that helps users connect the study with its disease context and genetics resources without changing any trial data.SummaryDifference0.2%

- Check60 days agoChange DetectedThe revision tag on the page updated from v3.6.4 to v3.6.5. This reflects a new version of the page in the revision history.SummaryDifference0.1%

Stay in the know with updates to Nivolumab and Relatlimab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and Relatlimab in Melanoma Clinical Trial page.